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Male patients presenting with rapidly progressive 
puberty associated with malignant tumors
Case report
In males, precocious puberty (PP) is defined as the development of secondary 
sexual characteristics before age 9 years. PP is usually idiopathic; though, organic 
abnormalities including tumors are more frequently found in male patients 
with PP. However, advanced puberty in male also can be an important clinical 
manifestation in tumors. We report 2 cases of rapidly progressive puberty in males, 
each associated with a germ-cell tumor. First, an 11-year-old boy presented with 
mild fever and weight loss for 1 month. Physical examination revealed a pubertal 
stage of G3P3 with 10-mL testes. Investigations revealed advanced bone age (16 
years) with elevated basal luteinizing hormone and testosterone levels. An anterior 
mediastinal tumor was identified by chest radiography and computed tomography, 
and elevated α-fetoprotein (AFP) and β-human chorionic gonadotropin (β-hCG) 
levels were noted. Histopathologic analysis confirmed a yolk-sac tumor. Second, 
a 12-year-old boy presented with diplopia, polydipsia, and polyuria for 4 months. 
Physical examination revealed a pubertal stage of G3P3 with 8-mL testes. Bone 
age was advanced (16 years) and laboratory tests indicated panhypopituitarism 
with elevated testosterone level. A mixed germ-cell tumor was diagnosed with 
elevated AFP and β-hCG levels. Of course, these patients also have other symptoms 
of suspecting tumors, however, rapidly progressive puberty can be the more earlier 
screening sign of tumors. Therefore, in male patients with accelerated or advanced 
puberty, malignancy should be considered, with evaluation of tumor markers. In 
addition, advanced puberty in male should be recognized more widely as a unique 
sign of neoplasm.
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Introduction
Precocious puberty (PP) can be defined as sexual maturation that occurs in children 2.5 
standard deviations of the mean earlier than in the normal population. The underlying causes 
of PP are usually benign or idiopathic with no evidence of organ lesions, especially in central 
precocious puberty and in girls1). While PP is relatively rare in boys, it is more likely to be 
associated with underlying diseases, such as congenital adrenal hyperplasia, McCune-Albright 
syndrome and several kinds of tumors2). It is therefore important to reliably identify the cause 
underlying each case of PP in boys. However, even when cases do not meet criteria for PP, 
accelerated pubertal velocity or advanced puberty can also reflect underlying disease. The 
pubertal course was considered accelerated if the transition from Tanner pubertal stage 2 to 3 
occurred within less than 1.5 years3). Here, we report 2 cases of rapidly progressive puberty in 
boys caused by neoplasm.
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Case reports
Case 1
An 11.7-year-old boy initially visited a local pediatric clinic 
because of mild fever, cough, and weight loss of about 4 kg in 
1 month. In his physical examination, tachycardia was also 
noted. The patient was referred to our pediatric endocrinology 
clinic for differential diagnosis of hyperthyroidism. He had no 
perinatal history. His past medical history and family medical 
history were not relevant except for a diagnosis of autism at 4–5 
years old. He did not show signs of hyperthyroidism, symptoms 
such as sweating, hot flash, tremor, and fatigue, but dyspnea 
was noted following exercise. In a physical examination, his 
height and weight placed him in the 75th–90th (151 cm) and 
the 10th–25th percentiles (34.2 kg), respectively, for his age and 
sex. He was found to have a Tanner pubertal stage of P3 with 
testicular volumes of 10 mL in both testicles. His pulse rate was 
90–100 per minute with tachycardia, but he had no goiter or 
exophthalmos.
A basal thyroid-function test was conducted for differential 
diagnosis of hyperthyroidism and chest radiography was 
performed because of the cough and mild fever. In addition, 
because of  the patient's advanced Tanner pubertal stage, 
hormonal studies were also performed. Thyroid function was 
found to be normal (T3, 0.52 ng/mL; normal range, 0.58–1.59 
ng/mL; free T4, 1.28 ng/dL; normal range, 0.70–1.48 ng/dL; 
and thyroid-stimulating hormone, 0.95 μIU/mL; normal range, 
0.35–4.49 μIU/mL) and thyroid-stimulating antibody was 
also negative. The patient’s luteinizing hormone (LH) level was 
appropriate for his age, but testosterone was elevated compared 
to normal values for the patient's age and sex (LH, 0.61 mIU/
mL; normal range, 0.2–5.0 mIU/mL; testosterone, 509.8 ng/
dL; normal range, 100–320 ng/dL). His bone age was advanced, 
estimated to be 16 years and to sum it up the results, he was just 
suspected rapidly progressive or advanced puberty. However, 
the initial chest radiography revealed multiple lung and pleural 
nodules and masses with right pleural effusion (Fig. 1). A chest 
computed tomography scan was performed and revealed an 
anterior mediastinal mass (5.4 cm×4.5 cm×6.0 cm) with lymph 
node, lung, and pleural metastases, suggesting a malignant germ-
cell tumor (GCT). Levels of tumor biomarkers were elevated, 
including α-fetoprotein (AFP), 20,509.21 ng/mL (normal range, 
0.6–3.9 ng/mL) and β-human chorionic gonadotropin (β-hCG), 
60 mIU/mL (normal range, <25 mIU/mL). Histopathologic 
examination of the mass by gun biopsy indicated a yolk-sac 
tumor.
The patient was scheduled for chemotherapy with bleomycin, 
cisplatin, and etoposide and during treatment, levels of serum 
AFP and β-hCG normalized in 3 months, but the mediastinal 
mass did not respond to treatment (Table 1). The patient 
then underwent an autologous peripheral blood stem-cell 
transplantation and wedge resection of the left lung. After 1 year, 
his height measured 153 cm (lower than the 3th percentile for 
adult height) and he had a closed epiphyseal plate.
Case 2
A 12.2-year-old boy presented with diplopia, polyuria, and 
polydipsia for 4 months and was referred to our hospital for 
further evaluation. He was diagnosed with a pineal-gland 
mixed GCTs without metastasis (Fig. 2). After surgical removal 
of the tumor, he was referred to our pediatric endocrinology 
clinic for pituitary hormone replacement. His past and family 
medical histories were unremarkable except for his pineal-gland 
mixed GCTs with elevated AFP (35.7 ng/mL; normal range, 
          
(A) (B) 
Fig. 1. (A) Chest radiograph showing multiple lung and pleural nodules and masses with right pleural effusion. (B) 
Left hand bone age radiograph at diagnosis. The arrow indicates lung and pleural nodules and masses.
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0.6–3.9 ng/mL) and serum β-hCG (2,642 mIU/mL; normal 
range, <25 mIU/mL). On physical examination, the patient's 
height and weight placed him in the 50th–75th (155 cm) and 
90th percentiles (57 kg), respectively. He was noted to have an 
advanced Tanner pubertal stage of P3 with testicular volumes of 
8-mL for both testicles.
Before surgery, a basal thyroid-function test showed hypothy-
roidism, with levels of T3 (0.65 ng/mL; normal range, 0.58–1.59 
ng/mL), free T4 (0.51 ng/dL; normal range, 0.70–1.48 ng/dL), 
and thyroid-stimulating hormone (1.01 μIU/mL; normal range, 
0.35–4.49 μIU/mL). Level of adrenocorticotropic hormone 
and cortisol was 4.08 pg/mL (normal range, 10–60 pg/mL) 
and 1.5 μg/dL (normal range, 5–23 μg/dL), respectively. His 
LH level was normal for his age and sex, but testosterone was 
elevated (LH, 0.36 mIU/mL; normal range, 0.2–5.0 mIU/mL; 
testosterone, 959.8 ng/dL; normal range, 100–320 ng/dL). His 
bone age was also advanced, at 16 years. After fluid restriction 
for differential diagnosis of diabetes insipidus, urine osmolality 
was 169 mOsm/kg while serum osmolality was 310 mOsm/
kg, consistent with diabetes insipidus. Based on physical 
          
(A) (B) 
Fig. 2. (A) Brain magnetic resonance imaging revealing mass lesions at pineal gland and suprasellar area. (B) Left 
hand bone age radiograph at diagnosis. The arrow indicates pineal gland and suprasellar area masses.
Table 1. Descriptive characteristics and hormone levels of 2 patients with advanced puberty
Characteristic Patient 1 Patient 2
Height (cm) 151 (75th–90th percentile) 155 (50th–75th percentile)
Weight (kg) 34.2 (10th–25th percentile) 57 (90th percentile)
Chronological age (yr) 11.7 12.2
Bone age (yr) 16 16
Basal level
  LH (mIU/mL) 0.61 0.36
  FSH (mIU/mL) <0.2 <0.2
  Testosterone (ng/dL) 509.8 959.8
  β-hCG (mIU/mL) 60 2,642
  AFP (ng/mL) 20,509.21 35.7
1 Month after chemotherapy
  β-hCG (mIU/mL) <0.1 4
  AFP (ng/mL) 1,434.7 -
2 Months after chemotherapy
  β-hCG (mIU/mL) <0.1 <0.1
  AFP (ng/mL) 14.33 3.38
3 Months after chemotherapy
  LH (mIU/mL) 3.68 0.26
  FSH (mIU/mL) 9.2 <0.2
  Testosterone (ng/dL) - <2.5
  β-hCG (mIU/mL) <0.1 <0.1
  AFP (ng/mL) 3.39 1.49
LH, luteinizing hormone; FSH, follicle-stimulating hormone; β-hCG, β-human chorionic gonadotropin; AFP, α-fetoprotein.
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examination and laboratory findings, the final diagnosis was 
mixed GCTs, multiple pituitary hormone insufficiency after 
surgery, and rapidly progressive puberty.
The patient was started on synthyroid (0.1 mg once daily), 
hysone (20 mg twice daily), and minirin (0.15 mg, 0.1 mg, 0.1 
mg, and 0.1 mg, daily). He received chemotherapy according 
to the KSPNO G082 protocol and was then treated with 
craniospinal irradiation with a total local dose of 39 Gy. During 
treatment, serum AFP and β-hCG levels normalized in 2 
months and his testosterone level normalized in 3 months (Table 
1). After 1 year, he reached an adult height (157 cm, lower than 
the 3th percentile for adults) and had a closed epiphyseal plate.
Discussion
Although the cause of PP is usually idiopathic or benign, 
malignancy can also cause PP. This possibility should be 
considered during evaluations of  puberty, in particular, 
among young, male children and in cases of pseudo-PP4). Of 
the various kinds of tumors that can cause PP by inducing 
excessive sex-hormone secretion, β-hCG-secreting GCTs 
may be the most commonly associated with PP5). GCTs are 
relatively rare and represent only 3% of all malignant tumors 
in childhood6). These are further divided into gonadal and 
extragonadal GCTs, and among the extragonadal GCTs, 
the central nervous system (CNS), retroperitoneum, and 
mediastinum are the most frequent sites. The initial clinical 
manifestations of GCTs depend on their particular location. 
CNS GCTs usually involve the hypothalamus and pituitary 
gland and can lead to diabetes insipidus, growth retardation 
and visual-field defects6). However, the other common sites for 
extragonadal GCTs do not have unique, distinguishing clinical 
features and so the diagnosis is sometimes delayed7). Fortunately, 
although only a small proportion of GCTs produce β-hCG, 
PP in boys may be a unique clinical manifestation of β-hCG-
secreting GCTs. Because β-hCG and LH possess an identical 
α-subunit and a similar β-subunit, the autonomous secretion 
of β-hCG can stimulate Leydig cells to produce testosterone8). 
In girls, elevated β-hCG secretion alone does not induce PP 
because follicle-stimulating hormone is required for ovarian 
estradiol production5). Therefore, pseudo-PP may be a clinical 
manifestation of β-hCG-secreting GCTs only in boys.
Even when patients do not meet the exact criteria for PP, 
subthreshold advanced puberty can still be caused by a tumor. 
According to Wendt et al.4), in 24 patients with PP caused by 
neoplasm, 29% had normal pubertal timing but accelerated 
pubertal velocity, as reflected by a more rapid progression 
through Tanner stages and more advanced bone age (more 
than 2 standard deviations above chronological age). This 
demonstrates that recognizing pathological variants of puberty 
requires not only age-based definitions of  PP, but also a 
thorough understanding of the normal spectrum of pubertal 
development. In particular, GCTs occur most frequently in the 
second decade of life and most children have begun puberty by 
this time9). In our 2 cases, patients were 11 and 12 years old and 
did not meet age-based definitions of PP; however, they had 
rapidly progressive puberty and malignancy. Of course, these 
patients had other symptoms suggestive of malignancy such as 
mild fever, weight loss, chronic cough, and diplopia. However, in 
the first case, these symptoms were not specific to the tumor, and 
the patient was treated for bronchitis for 1 month at his local 
clinic, delaying the diagnosis of a tumor. Lin et al.6) reported 
that about 60% of the patients with β-hCG-secreting GCTs 
exhibit symptoms and signs for more than 6 months before 
receiving the proper diagnosis. The authors suggested that a 
failure to recognize the initial clinical manifestations may partly 
account for these delayed diagnoses6,7). In our cases, accelerated 
or advance puberty can be an earlier clinical symptom than 
mild fever, weight loss and diplopia, and then not a typical 
pubertal development can be an initial screening manifestation. 
Therefore, concern regarding rapid growth and advanced 
puberty is necessary regardless of the diagnostic criteria used 
for PP.
When tumors are diagnosed, tumor treatment should 
become a priority over other treatment. However, normal 
growth and puberty should also be a target of interventions in 
children. After complete remission, the heights of our patients 
were evaluated, and unfortunately, the epiphyseal plate had 
already closed in both patients. They reached their adult height 
already, below the 3rd percentile. Neoplasm-induced pubertal 
acceleration and advanced puberty resulted in a too-short 
adult height, which may negatively impact their confidence10). 
Therefore, patients who have a malignancy such as a β-hCG-
secreting tumor or a sex-steroid-secreting tumor, such as an 
adrenocortical carcinoma, should be considered additionally for 
an evaluation of pubertal stages and growth status. In addition, a 
patient’s expected adult height is too short, sufficient explanation 
and moral support should be provided. Furthermore, because 
additional treatments may also be needed, a multidisciplinary 
approach is important.
In conclusion, we propose that male patients with rapid pro-
gressive or advanced puberty (not only PP) should be evaluated 
for signs of possible malignancy, and if malignancy is suspected, 
it should be considered with tests including the measurement 
of tumor biomarkers such as β-hCG. In addition, if a patient is 
diagnosed with a malignant tumor, multidisciplinary treatment 
should be implemented, targeting the tumor, growth, and 
puberty.
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